Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mixture of grass pollen allergen extracts is a biological preparation developed by Diater for the diagnosis and immunotherapy of grass pollen-related allergic conditions, including allergic rhinitis, conjunctivitis, and asthma. The mixture contains extracts from four specific grass species: *Phleum pratense* (timothy grass), *Lolium perenne* (perennial ryegrass), *Poa pratensis* (Kentucky bluegrass), and *Dactylis glomerata* (orchard grass). It functions by modulating the immune system's response to these allergens, typically through desensitization protocols that shift the immune profile from a Th2-mediated IgE response toward a Th1 or regulatory T-cell (Treg) response. The preparation has been evaluated in Phase 2 clinical trials in Spain for biological characterization and standardization using skin prick test responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mixture of grass pollen allergen extracts.